Grygiel Nancy A., an insider at Amgen Inc (AMGN), purchased 8,864 shares of the biotechnology company on November 19, 2025, at a price of $162.60 per share, amounting to a total transaction value of $1.44 million. Following this purchase, Grygiel holds 8,864 shares of Amgen.
This insider buying activity can serve as a positive indicator, as executives often have access to non-public information regarding their company's operations. Such transactions may suggest confidence in the company's future prospects.
However, investors should not base decisions solely on individual insider trades. Various personal or regulatory factors can influence these transactions. The Securities and Exchange Commission mandates that insider transactions be reported, providing transparency into how company executives view their stock.
Investors are encouraged to consider patterns of insider activity across multiple insiders and time periods, rather than focusing on isolated transactions. Amgen, headquartered in Thousand Oaks, California, operates in the human therapeutics segment and has a market capitalization of $184.4 billion. The company is known for its innovative products, including EPOGEN, Aranesp, and Repatha, and aims to address high unmet medical needs in biotechnology. Upcoming earnings are anticipated on April 29, 2026, with an estimated EPS of $5.16 and revenue of $8.8 billion.